Use and safety of unfractionated heparin for anticoagulation during maintenance hemodialysis.

Anticoagulation for atrial fibrillation in patients on dialysis: are the benefits worth the risks? Curr Opin Nephrol Hypertens (2012) 0.96

Use and safety of heparin-free maintenance hemodialysis in the USA. Nephrol Dial Transplant (2013) 0.94

The clinical significance and risk factors of anti-platelet factor 4/heparin antibody on maintenance hemodialysis patients: a two-year prospective follow-up. PLoS One (2013) 0.81

Bovine and porcine heparins: different drugs with similar effects on human haemodialysis. BMC Res Notes (2013) 0.80

The effect of citrate dialysate on intradialytic heparin dose in haemodialysis patients: study design of a randomised controlled trial. BMC Nephrol (2015) 0.77

Heparin use in hemodialysis patients following gastrointestinal bleeding. Am J Nephrol (2014) 0.75

Correlates and variance decomposition analysis of heparin dosing for maintenance hemodialysis in older US patients. Pharmacoepidemiol Drug Saf (2014) 0.75

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med (1995) 6.86

Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med (2008) 3.16

Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 3.07

Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 2.56

Elevated risk of stroke among patients with end-stage renal disease. Kidney Int (2003) 2.35

Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation (2009) 2.18

Association of heparin-dependent antibodies and adverse outcomes in hemodialysis patients: a population-based study. Mayo Clin Proc (2005) 2.17

Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int (2010) 2.10

Heparin stimulates Staphylococcus aureus biofilm formation. Infect Immun (2005) 2.04

Aspirin prescription and outcomes in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis (2007) 2.01

Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol (2009) 1.95

Association between vascular access failure and the use of specific drugs: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis (2002) 1.87

Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol (2011) 1.67

Pharmacodynamics of unfractionated heparin during and after a hemodialysis session. Am J Kidney Dis (2008) 1.64

Major bleeding in hemodialysis patients. Clin J Am Soc Nephrol (2007) 1.51

Risk factors for upper gastrointestinal bleeding among end-stage renal disease patients. Kidney Int (2003) 1.46

Hemodialysis using heparin-bound Hemophan in patients at risk of bleeding. Nephron Clin Pract (2004) 1.43

Evidence for high risk of cerebral hemorrhage in chronic dialysis patients. Kidney Int (1993) 1.42

Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep (2003) 1.39

Heparin-associated thrombocytopenia. Ann Intern Med (1984) 1.35

Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol (2008) 1.30

The direct thrombin inhibitor hirudin. Thromb Haemost (2008) 1.28

Trends in acute nonvariceal upper gastrointestinal bleeding in dialysis patients. J Am Soc Nephrol (2012) 1.27

Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials. J Am Soc Nephrol (2004) 1.26

Incidence, outcome, and risk factors of cerebrovascular events in patients undergoing maintenance hemodialysis. Am J Kidney Dis (1998) 1.17

Review article: Low-molecular-weight heparin as an alternative anticoagulant to unfractionated heparin for routine outpatient haemodialysis treatments. Nephrology (Carlton) (2009) 1.09

Unfractionated heparin for hemodialysis: still the best option. Semin Dial (2010) 1.07

Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol (2002) 1.06

Spontaneous retroperitoneal hemorrhage in chronically hemodialyzed patients. Nephron (1978) 1.06

Spontaneous retroperitoneal bleeding in patients on chronic hemodialysis. Ann Intern Med (1977) 1.05

Hemorrhagic pleural effusion in patients undergoing chronic hemodialysis. Ann Intern Med (1975) 1.03

Life-threatening anaphylactic shock caused by porcine heparin intravenous infusion during mitral valve repair. J Thorac Cardiovasc Surg (2003) 0.98

Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration. Kidney Int (1988) 0.97

Argatroban anticoagulation in renal dysfunction: a literature analysis. Nephron Clin Pract (2008) 0.96

Anticoagulation for intermittent hemodialysis. Semin Dial (2000) 0.95

Citrate for long-term hemodialysis: prospective study of 1,009 consecutive high-flux treatments in 59 patients. Am J Kidney Dis (2005) 0.94

Uremic hemopericardium. Am J Med (1968) 0.94

Heparins from porcine and bovine intestinal mucosa: Are they similar drugs? Thromb Haemost (2010) 0.94

Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation. Nephrol Dial Transplant (1999) 0.94

Heparin-induced hyperkalemia in chronic hemodialysis patients: comparison of low molecular weight and unfractionated heparin. Artif Organs (1998) 0.91

National survey of heparin-induced thrombocytopenia in the haemodialysis population of the UK population. Nephrol Dial Transplant (2007) 0.91

Section V. Chronic intermittent haemodialysis and prevention of clotting in the extracorporal system. Nephrol Dial Transplant (2002) 0.91

Rebound anticoagulation occurring after regional heparinization for hemodialysis. Trans Am Soc Artif Intern Organs (1966) 0.90

Comparison between tinzaparin and standard heparin for chronic hemodialysis in a Canadian center. Am J Nephrol (2002) 0.90

Role of platelet factor 4-heparin complex antibody (HIT antibody) in the pathogenesis of thrombotic episodes in patients on hemodialysis. Hemodial Int (2005) 0.90

Heparin free dialysis: comparative data and results in high risk patients. Kidney Int (1987) 0.89

Standard heparin versus low-molecular-weight heparin. A medium-term comparison in hemodialysis. Nephron (2002) 0.89

Anticoagulation rebound after hemodialysis. N Engl J Med (1966) 0.88

Assessment of the heparin-binding AN69 ST hemodialysis membrane: II. Clinical studies without heparin administration. ASAIO J (2005) 0.88

Effect of low molecular weight heparin on bone metabolism and hyperlipidemia in patients on maintenance hemodialysis. Int J Artif Organs (2001) 0.88

Antibodies to heparin-platelet factor 4 complex: pathogenesis, epidemiology, and management of heparin-induced thrombocytopenia in hemodialysis. Am J Kidney Dis (2009) 0.88

Sudden collapse during haemodialysis due to immune-mediated heparin-induced thrombocytopaenia. Nephrol Dial Transplant (2006) 0.87

Frequency of anti-heparin-PF4 complex antibodies (HIT antibodies) in uremic patients on chronic intermittent hemodialysis. Pathophysiol Haemost Thromb (2006) 0.87

Hemodialysis without anticoagulation. Am J Kidney Dis (1985) 0.87

Hemodialysis without anticoagulants: efficiency and hemostatic aspects. Clin Nephrol (1984) 0.87

Preventing hemorrhage in high-risk hemodialysis: regional versus low-dose heparin. Kidney Int (1979) 0.87

Spontaneous retroperitoneal hematoma. A complication of hemodialysis. JAMA (1974) 0.87

Heparin versus low molecular weight heparin K 2165 in chronic hemodialysis patients: a randomized cross-over study. Haemostasis (1986) 0.87

The clinical evaluation of low-dose heparin in haemodialysis: a prospective study using the heparin-coated AN69 ST membrane. Nephrol Dial Transplant (2007) 0.86

Is systemic heparin a risk factor for catheter-related sepsis in dialysis patients? An evaluation of various biofilm and traditional risk factors. Nephron Clin Pract (2007) 0.86

Heparin-induced thrombocytopenia. Blood Rev (1988) 0.86

Effects of conventional vs. low-molecular-weight heparin on lipid profile in hemodialysis patients. Am J Nephrol (1997) 0.86

Increased mortality in hemodialysis patients having specific antibodies to the platelet factor 4-heparin complex. Kidney Int (2007) 0.85

Heparin-induced thrombocytopenia in hemodialysis patients. Am J Kidney Dis (1996) 0.85

Risk factors of system clotting in heparin-free haemodialysis. Nephrol Dial Transplant (1990) 0.85

Improved dialyzer reuse after use of a population pharmacodynamic model to determine heparin doses. Am J Kidney Dis (2000) 0.84

Studies in regional heparinization. I. The use of simultaneous neutralization with protamine; preliminary studies. N Engl J Med (1956) 0.84

Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis. Thromb Haemost (2007) 0.84

Heparin-induced hyperkalemia. Arch Intern Med (1985) 0.84

Heparin-free hemodialysis with prophylactic change of dialyser and blood lines. Int J Artif Organs (1988) 0.83

The prevalence of antibodies to the platelet factor 4 -heparin complex and association with access thrombosis in patients on chronic hemodialysis. Thromb Res (2006) 0.83

Low molecular weight heparin does not necessarily reduce lipids and lipoproteins in hemodialysis patients. Clin Nephrol (1995) 0.83

Effect of haemodialysis on upper gastrointestinal tract pathology in patients with chronic renal failure. Nephrol Dial Transplant (1987) 0.83

Hemorrhage during high-risk hemodialysis using controlled heparinization. Nephron (1981) 0.82

Influence of low molecular weight heparin compared to conventional heparin for anticoagulation during haemodialysis on low density lipoprotein subclasses. Nephrol Dial Transplant (2002) 0.82

Lipoprotein lipase during heparin infusion: lower activity in hemodialysis patients. Scand J Clin Lab Invest (2003) 0.82

Warfarin use in hemodialysis patients: what is the risk? Clin Nephrol (2011) 0.81

Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay. Nephrol Dial Transplant (1995) 0.81

Long-term efficacy and safety of a low molecular weight heparin in chronic hemodialysis patients. A comparison with standard heparin. ASAIO Trans (1992) 0.81

Pseudopulmonary embolism: acute respiratory distress in the syndrome of heparin-induced thrombocytopenia. Am J Kidney Dis (1997) 0.81

When heparin causes thrombosis: significance, recognition, and management of heparin-induced thrombocytopenia in dialysis patients. Semin Dial (2006) 0.81

Dose finding study of a low molecular weight heparin, Innohep, in haemodialysis. Thromb Haemost (1991) 0.80

Risk factors leading to reduced bone mineral density in hemodialysis patients with metabolic syndrome. Ren Fail (2010) 0.80

Gordon Murray: heparin, hemodialysis and hubris. Am J Nephrol (2002) 0.80

Vitrectomy for diabetic retinopathy in patients undergoing hemodialysis for associated end-stage renal failure. Retina (1998) 0.80

Heparin-induced thrombocytopenia during renal replacement therapy. Hemodial Int (2004) 0.80

Reduced lipid concentrations during four years of dialysis with low molecular weight heparin. Kidney Int (1991) 0.80

Heparin elimination and hemostasis in hemodialysis. Clin Nephrol (1984) 0.80

Optimization of heparin anticoagulation for hemodialysis. Hemodial Int (2011) 0.80

The heparins: all a nephrologist should know. Nephrol Dial Transplant (2005) 0.79

Lipoprotein lipase in hemodialysis patients: indications that low molecular weight heparin depletes functional stores, despite low plasma levels of the enzyme. BMC Nephrol (2004) 0.79

Heparin-associated antiplatelet antibodies increase morbidity and mortality in hemodialysis patients. Surgery (2004) 0.79

Effect of a sliding scale protocol for heparin on the ability to maintain whole blood activated partial thromboplastin times within a desired range in hemodialysis patients. Clin Nephrol (1996) 0.79

Low-molecular-weight heparin (LMWH): influence on blood lipids in patients on chronic haemodialysis. Nephrol Dial Transplant (1993) 0.79

Low molecular weight heparin reduces triglyceride, VLDL and cholesterol/HDL levels in hyperlipidemic diabetic patients on hemodialysis. Am J Nephrol (1998) 0.79

Antibodies to platelet factor 4-heparin complex and outcome in hemodialysis patients with diabetes. Clin J Am Soc Nephrol (2010) 0.79

Precise anticoagulation for routine hemodialysis using nomograms. Trans Am Soc Artif Intern Organs (1978) 0.79

Rationale for the use of a low molecular weight heparin during hemodialysis with polysulphone membrane in uremic patients. Ann Ital Med Int (1997) 0.78

Pharmacokinetics and pharmacodynamics of heparin during hemodialysis: interpatient and intrapatient variability. Pharmacotherapy (1990) 0.78

Use of bovine lung heparin to obviate anaphylactic shock caused by porcine gut heparin. Ann Thorac Surg (1990) 0.78

Validity of International Classification of Diseases, Ninth Revision, Clinical Modification Codes for Acute Renal Failure. J Am Soc Nephrol (2006) 4.95

Hetastarch and bleeding complications after coronary artery surgery. Chest (2003) 2.87

The comparative short-term effectiveness of iron dosing and formulations in US hemodialysis patients. Am J Med (2013) 2.77

Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA (2010) 2.71

Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. J Am Coll Cardiol (2008) 2.58

A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int (2004) 2.29

Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol (2013) 2.06

Trends in the use and outcomes of implantable cardioverter-defibrillators in patients undergoing dialysis in the United States. Am J Kidney Dis (2011) 1.92

Preoperative statin use and postoperative acute kidney injury. Am J Med (2012) 1.87

Educational level as a determinant of access to and outcomes after kidney transplantation in the United States. Am J Kidney Dis (2008) 1.84

Nephrologist care and mortality in patients with chronic renal insufficiency. Arch Intern Med (2002) 1.82

Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004. Arthritis Rheum (2013) 1.80

Commentary on 'The DOPPS practice monitor for U.S. dialysis care: update on trends in anemia management 2 years into the bundle': iron(y) abounds 2 years later. Am J Kidney Dis (2013) 1.76

Delayed nephrologist referral and inadequate vascular access in patients with advanced chronic kidney failure. J Clin Epidemiol (2002) 1.73

Variation in nephrologist visits to patients on hemodialysis across dialysis facilities and geographic locations. Clin J Am Soc Nephrol (2013) 1.69

Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum (2011) 1.68

The hepatotoxicity of antifungal medications in bone marrow transplant recipients. Clin Infect Dis (2005) 1.67

Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010). JAMA Intern Med (2014) 1.58

Variation in initial kidney replacement therapy for end-stage renal disease due to lupus nephritis in the United States. Arthritis Care Res (Hoboken) (2011) 1.57

Predicting survival in patients requiring renal replacement therapy after cardiac surgery. Ann Thorac Surg (2006) 1.53

Long-term patient and graft survival in the eurotransplant senior program: a single-center experience. Transplantation (2005) 1.51

Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients. Pharmacoepidemiol Drug Saf (2008) 1.45

Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol (2006) 1.43

Multivessel coronary artery bypass grafting versus percutaneous coronary intervention in ESRD. J Am Soc Nephrol (2012) 1.42

Use of Medicare data to identify coronary heart disease outcomes in the Women's Health Initiative. Circ Cardiovasc Qual Outcomes (2014) 1.41

Validation of reported predialysis nephrology care of older patients initiating dialysis. J Am Soc Nephrol (2012) 1.36

Knowledge and attitude regarding organ donation among medical students and physicians. Transplantation (2004) 1.31

Surrogate markers in clinical studies: problems solved or created? Am J Kidney Dis (2006) 1.28

Trends in acute nonvariceal upper gastrointestinal bleeding in dialysis patients. J Am Soc Nephrol (2012) 1.27

How well do patients report noncompliance with antihypertensive medications?: a comparison of self-report versus filled prescriptions. Pharmacoepidemiol Drug Saf (2004) 1.24

Impact of Medicaid prior authorization on angiotensin-receptor blockers: can policy promote rational prescribing? Health Aff (Millwood) (2007) 1.22

Ten-year trends of cardiovascular drug use after myocardial infarction among community-dwelling persons > or =65 years of age. Am J Cardiol (2007) 1.21

End-stage renal disease due to lupus nephritis among children in the US, 1995-2006. Arthritis Rheum (2011) 1.17

The prevalence and cost of unapproved uses of top-selling orphan drugs. PLoS One (2012) 1.14

Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population. Arthritis Rheum (2012) 1.11

Trends in acute kidney injury, associated use of dialysis, and mortality after cardiac surgery, 1999 to 2008. Ann Thorac Surg (2012) 1.10

Saving the kidneys by sparing intravenous chloride? JAMA (2012) 1.07

Evolving statistical methods to facilitate evaluation of the causal association between erythropoiesis-stimulating agent dose and mortality in nonexperimental research: strengths and limitations. Am J Kidney Dis (2009) 1.07

Comparison of Medicare claims versus physician adjudication for identifying stroke outcomes in the Women's Health Initiative. Stroke (2014) 1.05

The 2011 ESRD prospective payment system: an uncontrolled experiment. Am J Kidney Dis (2011) 1.05

Differences in access to kidney transplantation between Hispanic and non-Hispanic whites by geographic location in the United States. Clin J Am Soc Nephrol (2013) 1.05

The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int (2003) 1.05

Patient and graft survival in older kidney transplant recipients: does age matter? J Am Soc Nephrol (2004) 1.02

Medication adherence after myocardial infarction: a long way left to go. J Gen Intern Med (2008) 1.01

Temporal trends in the incidence, treatment, and outcomes of hip fracture in older patients initiating dialysis in the United States. Clin J Am Soc Nephrol (2013) 1.01

The effect of altitude on dosing and response to erythropoietin in ESRD. J Am Soc Nephrol (2008) 1.00

Fostering innovation, advancing patient safety: the kidney health initiative. Clin J Am Soc Nephrol (2013) 1.00

Trends in the incidence of atrial fibrillation in older patients initiating dialysis in the United States. Circulation (2012) 0.99

Determinants of peritoneal dialysis technique failure in incident US patients. Perit Dial Int (2012) 0.99

Trends in relative mortality between Hispanic and non-Hispanic whites initiating dialysis: a retrospective study of the US Renal Data System. Am J Kidney Dis (2013) 0.99

Chronic on acute renal failure: long-term implications of severe acute kidney injury. JAMA (2009) 0.98

Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL. Pharmacoepidemiol Drug Saf (2009) 0.97

Hispanic ethnicity and vascular access use in patients initiating hemodialysis in the United States. Clin J Am Soc Nephrol (2011) 0.96

Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients. PLoS One (2013) 0.96

Anticoagulation for atrial fibrillation in patients on dialysis: are the benefits worth the risks? Curr Opin Nephrol Hypertens (2012) 0.96

Kidney function and long-term medication adherence after myocardial infarction in the elderly. Clin J Am Soc Nephrol (2011) 0.95

Use and safety of heparin-free maintenance hemodialysis in the USA. Nephrol Dial Transplant (2013) 0.94

Gender differences in the management and prognosis of myocardial infarction among patients > or = 65 years of age. Am J Cardiol (2008) 0.94

Prognostic associations of serum calcium, phosphate and calcium phosphate concentration product with outcomes in kidney transplant recipients. Transpl Int (2007) 0.93

Comparative effectiveness research: what is it and why do we need it in nephrology? Nephrol Dial Transplant (2012) 0.92

Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice. Heart (2007) 0.92

Long-term trends of angiotensin-converting enzyme inhibitor and angiotensin-receptor blocker use after heart failure hospitalization in community-dwelling seniors. Int J Cardiol (2007) 0.91

Comparison of two dosages of thymoglobulin used as a short-course for induction in kidney transplantation. Transpl Int (2006) 0.91

Cardiovascular risk and the thiazolidinediones: déjà vu all over again? JAMA (2007) 0.91

Treated and untreated kidney failure in older adults: what's the right balance? JAMA (2012) 0.90

Phosphate binder choice in dialysis patients: a call for evidence-based rather than marketing-based clinical practice. Am J Kidney Dis (2008) 0.89

Medication issues in older individuals with CKD. Adv Chronic Kidney Dis (2010) 0.88

Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure. Circulation (2005) 0.88

Early erythropoietin therapy is associated with improved growth in children with chronic kidney disease. Pediatr Nephrol (2007) 0.87

ACE inhibitor and angiotensin II type 1 receptor antagonist therapies in elderly patients with diabetes mellitus: are they underutilized? Drugs Aging (2010) 0.87

World Kidney Day 2011. J Am Soc Nephrol (2011) 0.87

Associations between demographic factors and provider structures on cost and length of stay for hemodialysis patients with vascular access failure. Clin J Am Soc Nephrol (2006) 0.87

Methionine synthase reductase MTRR 66A > G has no effect on total homocysteine, folate, and Vitamin B12 concentrations in renal transplant patients. Atherosclerosis (2004) 0.86

Risk factors of short-term mortality after acute nonvariceal upper gastrointestinal bleeding in patients on dialysis: a population-based study. BMC Nephrol (2013) 0.86

Near-term prediction of sudden cardiac death in older hemodialysis patients using electronic health records. Clin J Am Soc Nephrol (2013) 0.86

Renal dysfunction increases the risk of saphenous vein graft occlusion: results from the Post-CABG trial. Atherosclerosis (2006) 0.86

Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients. Clin Nephrol (2012) 0.84

Prognostic associations between lipid markers and outcomes in kidney transplant recipients. Am J Kidney Dis (2006) 0.84

Epidemiologic and statistical methods for comparative effectiveness research. Heart Fail Clin (2012) 0.84

Lessons from geographic variations in predialysis nephrology care. J Am Soc Nephrol (2009) 0.84

Incidence, correlates, and consequences of acute kidney injury in patients with pulmonary arterial hypertension hospitalized with acute right-side heart failure. J Card Fail (2011) 0.83

The association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use during postischemic acute transplant failure and renal allograft survival. Transplantation (2006) 0.83

Propensity scores in the presence of effect modification: A case study using the comparison of mortality on hemodialysis versus peritoneal dialysis. Emerg Themes Epidemiol (2010) 0.83

Posttransplantation anemia: mechanisms and management. Clin J Am Soc Nephrol (2011) 0.83

What caused excess strokes in patients randomized to darbepoetin in the trial to reduce cardiovascular events with Aranesp therapy (TREAT)?: no smoking gun. Circulation (2011) 0.83

Comparing the costs, risks, and benefits of competing strategies for the primary prevention of venous thromboembolism. Circulation (2004) 0.83

On the relative safety of intravenous iron formulations: new answers, new questions. Am J Hematol (2010) 0.82

Effect of conversion from ciclosporin to tacrolimus on endothelial progenitor cells in stable long-term kidney transplant recipients. Transplantation (2013) 0.81

Endothelial progenitor cells in kidney transplant recipients. Transplantation (2006) 0.81

Angiotensin-converting enzyme inhibitors and cardiovascular outcomes in patients on maintenance hemodialysis. Am Heart J (2011) 0.80

Genetic aspects of hyperhomocysteinemia in chronic kidney disease. Semin Nephrol (2006) 0.79

Trends in the incidence of intestinal perforation in US dialysis patients (1992-2005). J Nephrol (2012) 0.79

The effect of altitude change on anemia treatment response in hemodialysis patients. Am J Epidemiol (2011) 0.79

Analysis of the cardiovascular risk profile in stable kidney transplant recipients after 50% cyclosporine reduction. Clin Transplant (2004) 0.78

Against TREATing all patients alike: lessons from an FDA Advisory Committee Meeting. J Am Soc Nephrol (2010) 0.78

Quantifying the benefit of early living-donor renal transplantation with a simulation model of the Dutch renal replacement therapy population. Nephrol Dial Transplant (2011) 0.78

Nononcologic use of human recombinant erythropoietin therapy in hospitalized patients. Arch Intern Med (2007) 0.78

Strategies for the management of suspected heparin-induced thrombocytopenia: a cost-effectiveness analysis. Pharmacoeconomics (2007) 0.78

Kidney disease and antihypertensive medication adherence: the need for improved measurement tools. Am J Kidney Dis (2010) 0.77

More evidence on an abominable pairing: atrial fibrillation and kidney disease. Circulation (2013) 0.77